Last reviewed · How we verify
Immunose™ FLU 1%
At a glance
| Generic name | Immunose™ FLU 1% |
|---|---|
| Sponsor | Eurocine Vaccines AB |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU (PHASE1, PHASE2)
- Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunose™ FLU 1% CI brief — competitive landscape report
- Immunose™ FLU 1% updates RSS · CI watch RSS
- Eurocine Vaccines AB portfolio CI